Change of Adviser and Broker

RNS Number : 4071G
Oxford Biomedica PLC
06 June 2013
 

 

 

 

 

 

 

Oxford BioMedica plc Change of Adviser and Broker

 

Oxford, UK - 6 June 2013: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it has appointed Nomura Code Securities Limited as its sponsor, financial adviser and broker with immediate effect.

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

 

Tel: +44 (0)1865 783 000

 

Nomura Code Securities

Juliet Thompson

Jonathan Senior

Christopher Golden

 

 

Tel: +44 (0)20 7776 1200

Media Enquiries:

Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications

Tel: +44 (0)20 7920 2360

 

 

Notes to editors

 

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

APPUGUBGQUPWGQA